BML-210
SIGMA/B8063 - ≥98% (HPLC), powder
Synonym: N1-
CAS Number: 537034-17-6
Empirical Formula (Hill Notation): C20H25N3O2
Molecular Weight: 339.43
MDL Number: MFCD08062139
Linear Formula: C20H25N3O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to very faintly yellow |
| form | powder |
| InChI | 1S/C20H25N3O2/c21-17-12-8 |
| InChI key | RFLHBLWLFUFFDZ-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | Nc1ccccc1NC(=O)CCCCCCC(=O |
| solubility | DMSO: >20 mg/mL |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | BML-210 is a histone deacetylase inhibitor. Treatment of A549 cells with BML-210 results in a dose-dependent increase in acetylated histone levels (EC50 = 36 μM). In HeLa extracts, the IC50 for inhibition of HDAC activity is 80 μM. |
| Biochem/physiol Actions: | BML-210 is a synthetic benzamide and is a potential tumor inhibitor. It is used as a therapeutic agent to treat promyelocytic leukemia. In human leukemia cell lines (NB4, HL-60, THP-1, and K562), BML-210 modulates histone deacetylase and promotes apoptosis. BML-210 favors frataxin expression in neurodegenerative disease Friedreich′s ataxia (FRDA). It interacts with myocyte enhancer factor-2 (MEF2) via hydrogen-bonding and prevents histone deacetylase 4 (HDAC4) binding. |
| Biochem/physiol Actions: | BML-210 is an HDAC inhibitor. |
| Features and Benefits: | This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Packaging: | 5, 25 mg in glass bottle |
| Hazard statements | H413 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |

